Does Metformin Extend Life? What the Evidence Actually Shows

Metformin is the world's most-prescribed diabetes pill — over 150 million people take it every day. For the past decade it has also been the most-hyped "longevity drug." The pitch sounds almost too good: diabetics who take metformin seem to outlive people without diabetes. Does that mean it can add years to a healthy person's life? Here's what the evidence actually says — and where it falls short.

📋 Simple Summary

Metformin is a cheap, decades-old diabetes drug. Studies of millions of people show that diabetics who take it tend to live longer than people who don't — even longer than people without diabetes.

That sounds amazing. But those studies only watched what already happened; they don't prove metformin caused the longer life. So the honest answer is: metformin looks promising and has an excellent 60-year safety record, but we don't yet have proof it extends life in healthy people.

A big trial called TAME is running right now to give us that proof. And one more thing — metformin is a prescription drug, not a supplement you can grab off a shelf.

The detailed breakdown continues below for those who want the full science.

🥈 Evidence Tier: Silver

The human data is large and remarkably consistent — a 53-study review and a 180,000-person cohort both point the same way. But it's all observational, meaning researchers watched what already happened rather than randomly assigning people to take metformin or not. That leaves room for other differences between metformin users and non-users to explain the results. The "gold standard" test — a randomized trial in healthy people — is exactly what's still missing. That's why this is Silver, not Gold.

The short answer

In people with diabetes, metformin users consistently live longer than diabetics on other drugs — and in one famous study, slightly longer than matched people without diabetes. In healthy, non-diabetic people, we simply don't know yet, because the first big randomized trial is still running.

Metformin is not FDA-approved for anti-aging, and it is a prescription drug, not a supplement.

What is metformin?

Metformin belongs to a class of drugs called biguanides. It was originally derived from a plant called French lilac (Galega officinalis), used in folk medicine for centuries. It lowers blood sugar mainly by reducing how much sugar your liver pumps out and by making your muscles more sensitive to insulin — the hormone that lets your cells absorb sugar.

For longevity, the more interesting part is what it does inside cells. Metformin flips on a switch called AMPK — think of it as the cell's "low-energy alarm" that triggers cleanup and repair. Flipping this switch is one reason metformin may act like a mild version of the healthy stress your body gets from exercise or eating less.

The evidence, study by study

The 53-study review (Campbell et al., 2017)

Researchers pooled data from 53 studies comparing metformin users to other groups. A key number to know here is the hazard ratio — a measure of how much more or less likely someone is to die, where 1.0 means "no difference." Below 1.0 means lower risk. They found:

Diabetics on metformin had a 7% lower risk of dying from any cause than matched non-diabetics (hazard ratio 0.93).
Compared to diabetics on other drugs, metformin users did even better: 28% lower death risk vs other pills, 32% lower vs insulin, and 20% lower vs an older drug class called sulphonylureas.
Metformin users also had about 6% less cancer and about 24% less heart disease.

Why it matters: this is the biggest, most consistent picture we have. But because it's observational, the authors themselves warn the differences could partly come from other factors.

The "outliving non-diabetics" study (Bannister et al., 2014)

This is the study that made headlines. Researchers tracked 180,926 people in the UK for years:

78,241 diabetics on metformin died at a rate of 14.4 per 1,000 people per year.
90,463 matched people without diabetes died at a rate of 15.2 per 1,000.
So the metformin users actually died slightly less often than healthy non-diabetics.
For contrast, diabetics on sulphonylureas died at a much higher rate — 50.9 per 1,000.

Why it matters: it's a striking result, but it compares people who were prescribed different drugs. A doctor might prescribe metformin to a healthier patient and sulphonylureas to a sicker one — a problem researchers call "channelling bias," which can make metformin look better than it truly is.

The mechanism (Kulkarni et al., 2020)

A review led by Dr. Nir Barzilai — the scientist behind the TAME trial — summarized how metformin touches the "hallmarks of aging." In lab and animal work, metformin has been shown to:

Improve how cells sense and use energy
Boost autophagy — the cell's internal cleanup-and-recycling system
Reduce senescence — the "zombie cells" that stop dividing but keep pumping out inflammation
Protect DNA and slow telomere shortening (telomeres are the protective caps on chromosomes that wear down with age)

The real test: the TAME trial

TAME stands for "Targeting Aging with Metformin." It's the first trial ever designed to test whether a drug can delay the onset of age-related disease — not treat one disease, but slow the whole aging process. It plans to follow roughly 3,000 healthy adults aged 65–79 taking 1,500 mg of metformin a day for 6 years.

If TAME shows metformin delays heart disease, cancer, and dementia in otherwise healthy people, it would be the first real proof that a drug can slow human aging. It's still running — no results yet.

Our Take

Metformin has the strongest safety record of any candidate "longevity drug" — 60 years of use, over 150 million people, and it's cheap. The observational signal linking it to longer life is real and consistent across dozens of studies.

But "linked to" is not the same as "causes." Until a randomized trial shows metformin actually extends life in healthy people, the honest label is promising, not proven. And because it's a prescription drug with real side effects, taking it off-label for aging is a decision for you and your doctor — not a supplement you grab off a shelf.

❓ Common Questions About Metformin and Longevity

What is metformin and how does it work?

Metformin is a prescription diabetes drug, not a supplement. It lowers blood sugar by reducing how much sugar your liver makes and helping muscles respond to insulin. For longevity, the interesting part is that it activates AMPK — a cellular "low-energy" switch that triggers repair and cleanup, similar to the healthy stress from exercise or eating less.

What does the evidence actually show?

Large observational studies consistently link metformin to lower death rates. A 53-study review found diabetics on metformin were 7% less likely to die than matched non-diabetics, and 20–32% less likely than diabetics on other drugs. But these are observational, so they show a link, not proof of cause.

What's the right dose?

There is no established "longevity dose." The diabetes dose is typically 500–850 mg, one to three times a day, up to about 2,000 mg. The TAME trial is testing 1,500 mg a day in healthy older adults. Because metformin is prescription-only, any dose is a decision for your doctor — not a self-directed supplement.

What are the risks and side effects?

The most common side effects are stomach problems — nausea, diarrhea, and an upset stomach — which usually improve over time. Long-term use can lower vitamin B12 levels. A rare but serious risk is lactic acidosis, a dangerous acid buildup, mostly in people with kidney or liver problems.

Who should avoid it?

People with significant kidney disease or liver disease should avoid metformin, and it's not recommended during certain acute illnesses. Most importantly, healthy people should not take it off-label for anti-aging — it's a prescription drug, not a supplement, and the evidence for that use isn't there yet. Talk to your doctor.

The Bottom Line

What we know: In people with diabetes, metformin is consistently linked to living longer — and to less cancer and heart disease. The observational evidence is large and consistent.

What we don't know: Whether it extends life in healthy, non-diabetic people. That's what the TAME trial is testing, and it's not finished.

What to do with this: If you have diabetes, metformin is a proven first-line treatment — talk to your doctor. If you're healthy and curious about metformin for aging, the evidence isn't there yet to justify taking it off-label, and it's not FDA-approved for that use.

⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Metformin is a prescription medication — never start, stop, or change it without talking to your own doctor. Talk to your doctor before starting any supplement or changing your health routine.

Sources

Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Research Reviews. 2017. PMID 28802803
Bannister CA, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity & Metabolism. 2014. PMID 25041462
Kulkarni AS, Gubbi S, Barzilai N. Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metabolism. 2020. PMID 32333835
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metabolism. 2016. PMID 27304507
Guarente L, Sinclair DA, Kroemer G. Human trials exploring anti-aging medicines. Cell Metabolism. 2024. PMID 38181790